Google
HCM Stock Analysis — HUTCHMED DRC (Healthcare >> Drug Manufacturers - Specialty & Generic)
HCM FAQ
What is HCM's P/E ratio?
HUTCHMED DRC (HCM) currently trades at a P/E ratio of 4.25.
What is HCM's ROE?
HUTCHMED DRC reports a Return on Equity (ROE) of 37.01%.
What is HCM's dividend yield?
HUTCHMED DRC offers a dividend yield of 0.00%.
What is HCM's Quality Score?
Our AI rates HCM's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HCM?
Our AI Timing Score for HCM is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HCM belong to?
HUTCHMED DRC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange
HCM AI Analysis Summary
Our AI summary for HCM: HUTCHMED DRC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 4.25, ROE of 37.01%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 11.13
Price
0.36
(3.34%)
Day Change
|
|
|---|
HCM, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Historical ROE is relatively low
Negative growth of ROE in the last year.
Growth of ROA was below our criteria in the last year.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
63% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
803
|
| Magic Formula Rank by ROE |
803
|
| Magic Formula Rank by ROIC |
215
|
| Price | 11.13 |
| PBV / Sector |
1.55 / 3.22
GOOD
|
| Earning Per Share | 2.62 |
| PE / Sector |
4.25 / 29.79
GREAT
|
| PEG or PE/Growth / Sector |
-0.04 / 0.13
|
| Average 1M Daily Value |
0.52 M
GREAT
|
| Average 1W Daily Value |
0.46 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
72% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:57 |
| Symbol | HCM |
| Name | HUTCHMED DRC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 173.81 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,943.78 / 10,754.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Cheung Kong Center, Hong Kong, Hong Kong
Phone: 852 2121 8200
Website: https://www.hutch-med.com
Employees: 1,796
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Drug Manufacturers - Specialty & GenericAnalysed on the same criteria, ordered by market cap